Panbela Provides Business Update and Reports Q1 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
H.C. Wainwright Downgrades Panbella Therapeutics (PBLA) to Neutral
May 16, 2024 11:31 AM EDTH.C. Wainwright analyst Joseph Pantginis downgraded Panbella Therapeutics (NASDAQ: PBLA) from Buy to Neutral.
The analyst comments "Yesterday after the close, Panbela announced 1Q24 results, posting 1Q24 EPS of ($2.28) compared with our estimate of ($1.23) and consensus of ($1.62). The company ended the quarter with $262,000 in cash. Per management, current cash burn... More
